Balance Sheet: Liabilities and Stockholders’ Equity

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Eli Lilly & Co., consolidated balance sheet: liabilities and stockholders’ equity

US$ in thousands

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Short-term borrowings and current maturities of long-term debt	5,117,100)	6,904,500)	1,501,100)	1,538,300)	8,700)
Accounts payable	3,228,600)	2,598,800)	1,930,600)	1,670,600)	1,606,700)
Employee compensation	2,093,900)	1,650,400)	1,059,800)	958,100)	997,200)
Sales rebates and discounts	11,539,300)	11,689,000)	8,784,100)	6,845,800)	5,853,000)
Dividends payable	1,346,300)	1,169,200)	1,017,200)	885,500)	770,600)
Other current liabilities	5,051,400)	3,281,300)	2,845,400)	3,154,400)	3,245,400)
Current liabilities	28,376,600)	27,293,200)	17,138,200)	15,052,700)	12,481,600)
Long-term debt, excluding current maturities	28,527,100)	18,320,800)	14,737,500)	15,346,400)	16,586,600)
Accrued retirement benefits	1,300,500)	1,438,800)	1,305,100)	1,954,100)	4,094,500)
Long-term income taxes payable	4,060,900)	3,849,200)	3,709,600)	3,920,000)	3,837,800)
Other noncurrent liabilities	2,178,200)	2,240,600)	1,824,000)	3,378,000)	3,807,400)
Noncurrent liabilities	36,066,700)	25,849,400)	21,576,200)	24,598,500)	28,326,300)
Total liabilities	64,443,300)	53,142,600)	38,714,400)	39,651,200)	40,807,900)
Common stock, no par value	592,400)	593,600)	594,100)	596,300)	598,200)
Additional paid-in capital	7,439,300)	7,250,400)	6,921,400)	6,833,400)	6,778,500)
Retained earnings	13,545,000)	10,312,300)	10,042,600)	8,958,500)	7,830,200)
Employee benefit trust	(3,013,200)	(3,013,200)	(3,013,200)	(3,013,200)	(3,013,200)
Accumulated other comprehensive loss	(4,321,900)	(4,327,000)	(3,844,600)	(4,343,100)	(6,496,400)
Cost of common stock in treasury	(49,500)	(44,200)	(50,500)	(52,700)	(55,700)
Total Eli Lilly and Company shareholders’ equity	14,192,100)	10,771,900)	10,649,800)	8,979,200)	5,641,600)
Noncontrolling interests	79,500)	91,800)	125,600)	175,600)	183,600)
Total equity	14,271,600)	10,863,700)	10,775,400)	9,154,800)	5,825,200)
Total liabilities and equity	78,714,900)	64,006,300)	49,489,800)	48,806,000)	46,633,100)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Download chart

Balance sheet item	Description	The company
Current liabilities	Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.	Eli Lilly & Co. current liabilities increased from 2022 to 2023 and from 2023 to 2024.
Noncurrent liabilities	Amount of obligation due after one year or beyond the normal operating cycle, if longer.	Eli Lilly & Co. noncurrent liabilities increased from 2022 to 2023 and from 2023 to 2024.
Total liabilities	Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.	Eli Lilly & Co. total liabilities increased from 2022 to 2023 and from 2023 to 2024.
Total Eli Lilly and Company shareholders’ equity	Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.	Eli Lilly & Co. total Eli Lilly and Company shareholders’ equity increased from 2022 to 2023 and from 2023 to 2024.

Eli Lilly & Co. (NYSE:LLY)

Balance Sheet: Liabilities and Stockholders’ Equity